{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:07:46Z","timestamp":1788952066318,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000982","name":"ASCO Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clbc.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:18:55Z","timestamp":1787411935000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Endocrine Therapies: Current Status and Future Directions"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9929-8852","authenticated-orcid":false,"given":"Elena","family":"Brierley-Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Duggirala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-6383","authenticated-orcid":false,"given":"Marla","family":"Lipsyc-Sharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2026.07.010_sbref0001","series-title":"Breast cancer","year":"2024"},{"key":"10.1016\/j.clbc.2026.07.010_bib0003","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: elacestrant (ORSERDU); Accessed July 20, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217639Orig1s000correctedlbl.pdf"},{"key":"10.1016\/j.clbc.2026.07.010_bib0004","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: fulvestrant (FASLODEX); Accessed July 20, 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021344s044lbl.pdf"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.010_bib0005","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1097\/MS9.0000000000002293","article-title":"Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review","volume":"86","author":"Qureshi","year":"2024","journal-title":"Ann Med Surg"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00483-1","article-title":"Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer","volume":"8","author":"Pancholi","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.010_bib0007","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s13318-020-00635-3","article-title":"Pharmacokinetic and pharmacodynamic studies of Elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women","volume":"45","author":"Conlan","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"23","key":"10.1016\/j.clbc.2026.07.010_bib0008","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor\u2013positive\/Human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.010_bib0073","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/ERC-15-0287","article-title":"Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader","volume":"22","author":"Wardell","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"10.1016\/j.clbc.2026.07.010_bib0009","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2\u2212 metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the Phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.clbc.2026.07.010_bib0011","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS619","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.010_bib0049","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/JCO.20.02272","article-title":"Phase I study of Elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer","volume":"39","author":"Bardia","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.010_bib0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-020-01333-3","article-title":"A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET\/CT imaging","volume":"22","author":"Jager","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"35","key":"10.1016\/j.clbc.2026.07.010_bib0017","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1200\/JCO.23.02733","article-title":"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: phase Ia\/Ib EMBER study","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.010_bib0018","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0019","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2025.43.16_suppl.1060","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): safety analyses from the phase III EMBER-3 trial","volume":"43","author":"O\u2019Shaughnessy","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2025.43.16_suppl.1001","article-title":"Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator\u2019s choice standard endocrine therapy, or imlunestrant + abemaciclib: results from the phase III EMBER-3 trial","volume":"43","author":"Curigliano","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0053","author":"Datta-Mannan"},{"issue":"17_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4","volume":"43","author":"Turner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.010_bib0023","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.010_bib0024","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.010_bib0029","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.clbc.2026.07.010_bib0030","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor\u2013Positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.010_bib0054","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1124\/dmd.124.001688","article-title":"Mass balance, metabolic pathways, absolute bioavailability, and pharmacokinetics of giredestrant in healthy subjects","volume":"52","author":"Kshirsagar","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clbc.2026.07.010_bib0010","unstructured":"Kaklamani VG EMERALD Phase 3 trial of Elacestrant versus Standard of care endocrine therapy in patients with ER+\/HER2- metastatic breast cancer: updated results by duration of prior CDK4\/6i in metastatic setting; Accessed July 16, 2025. Available at: https:\/\/www.onclive.com\/view\/emerald-phase-3-trial-of-elacestrant-versus-standard-of-care-endocrine-therapy-in-patients-with-er-her2\u2013metastatic-breast-cancer-updated-results-by-duration-of-prior-cdk4-6i-in-metastatic-setting."},{"issue":"8","key":"10.1016\/j.clbc.2026.07.010_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/fon-2022-1196","article-title":"Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment","volume":"19","author":"Turner","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_sbref0026","series-title":"Switching to Camizestrant after Detection of an ESR1 Mutation Improves Progression-Free Survival for some Patients with Advanced Breast Cancer","year":"2025"},{"key":"10.1016\/j.clbc.2026.07.010_sbref0027","series-title":"SERENA-6: ctDNA-Guided Treatment Switch to Camizestrant Before Clinical Progression Improves Outcomes in ESR1-Mutated, HR-Positive\/HER2-Negative Advanced Breast Cancer","year":"2025"},{"key":"10.1016\/j.clbc.2026.07.010_bib0060","series-title":"Paper presented at: 2025 ESMO Congress; October 17-21","author":"Mayer","year":"2025"},{"key":"10.1016\/j.clbc.2026.07.010_bib0069","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.23.02036","article-title":"Randomized phase III study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: primary results from AMEERA-5","volume":"42","author":"Cort\u00e9s","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.010_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101377","article-title":"188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+\/HER2\u2212 advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy","volume":"8","author":"Cort\u00e9s","year":"2023","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0012","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2024.42.16_suppl.1069","article-title":"Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv\/mBC): preliminary data from ELEVATE, a phase 1b\/2, open-label, umbrella study","volume":"42","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_sbref0015","series-title":"Elacestrant vs Elacestrant Plus A CDK4\/\u200b6 Inhibitor in Patients with ERpositive\/\u200bHER2-negative Advanced or Metastatic Breast Cancer","year":"2023"},{"key":"10.1016\/j.clbc.2026.07.010_bib0021","author":"Stallard"},{"issue":"8","key":"10.1016\/j.clbc.2026.07.010_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100110","volume":"53","author":"Gangl","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"10.1016\/j.clbc.2026.07.010_bib0078","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.010_bib0079","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0077","author":"Ryan"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.2026.44.16_suppl.502","article-title":"Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor\u2013positive, HER2-negative early breast cancer (ER+, HER2\u2013 eBC) in the phase III lidERA BC clinical trial: results by menopausal status","volume":"44","author":"Schmid","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0081","series-title":"Giredestrant Cuts Recurrence Risk Across Menopausal Status in ER+\/HER2- Early Breast Cancer","author":"Inman","year":"2026"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0083","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1200\/JCO.2026.44.16_suppl.1016","volume":"44","author":"Jhaveri","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0031","author":"Roche"},{"key":"10.1016\/j.clbc.2026.07.010_bib0032","author":"Oncotech"},{"key":"10.1016\/j.clbc.2026.07.010_bib0033","author":"Roche"},{"key":"10.1016\/j.clbc.2026.07.010_bib0070","unstructured":"Genentech provides update on phase III persevErA study in ER-positive advanced breast cancer; 2026. Available at: https:\/\/www.gene.com\/media\/press-releases\/15106\/2026-03-08\/genentech-provides-update-on-phase-iii-p."},{"issue":"24","key":"10.1016\/j.clbc.2026.07.010_bib0034","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: randomized Phase II study of amcenestrant (Oral Selective Estrogen Receptor Degrader) versus standard endocrine monotherapy in estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: a graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell Signal"},{"key":"10.1016\/j.clbc.2026.07.010_sbref0036","series-title":"VERITAC-2: Vepdegestrant Delivers Significantly Longer PFS than Fulvestrant in ESR1-Mutated, ER-Positive\/HER2-Negative Advanced Breast Cancer","year":"2025"},{"issue":"17_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0037","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1000","article-title":"Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer: results of the global, randomized, phase 3 VERITAC-2 study","volume":"43","author":"Hamilton","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0068","unstructured":"Rosa K FDA grants fast track status to Vepdegestrant for ER+\/HER2\u2013 Metastatic breast cancer; 2024. Available at: https:\/\/www.onclive.com\/view\/fda-grants-fast-track-status-to-vepdegestrant-for-er-her2-metastatic-breast-cancer"},{"key":"10.1016\/j.clbc.2026.07.010_bib0075","unstructured":"FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer; 2026. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast."},{"key":"10.1016\/j.clbc.2026.07.010_bib0076","unstructured":"VEPPANU (vepdegestrant) tablets, for oral use prescribing information; 2026. Available at: https:\/\/www.arvinas.com\/wp-content\/uploads\/2026\/05\/NDA-219835_Approval-Rx-ONLY.pdf."},{"issue":"5","key":"10.1016\/j.clbc.2026.07.010_bib0055","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J Pharma Anal"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.010_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-025-02049-y","article-title":"Palazestrant, a novel oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), in patients with ER+\/HER2\u2212\u2009advanced or metastatic breast cancer: phase 1\/2 study results","volume":"27","author":"Hamilton","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"4_Suppl","key":"10.1016\/j.clbc.2026.07.010_bib0045","article-title":"Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - a phase II study","volume":"82","author":"Hamilton","year":"2022","journal-title":"Cancer Res"},{"issue":"4_Suppl","key":"10.1016\/j.clbc.2026.07.010_bib0056","article-title":"Abstract PS12-15: pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2- BC)","volume":"81","author":"Majid","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.07.010_sbref0057","series-title":"Bazedoxifene","author":"Raina","year":"2025"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.010_bib0058","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"De Villiers","year":"2011","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.010_bib0062","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2\u2212 metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2026.07.010_bib0064","unstructured":"Lasofoxifene In: DrugBank Online. DrugBank. Available at: https:\/\/go.drugbank.com\/drugs\/DB06202"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.010_bib0039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1535-7163.MCT-23-0351","article-title":"Palazestrant (OP-1250), a complete estrogen receptor antagonist, inhibits wild-type and mutant ER-positive breast cancer models as monotherapy and in combination","volume":"23","author":"Parisian","year":"2024","journal-title":"Mol Cancer Therap"},{"issue":"9_Suppl","key":"10.1016\/j.clbc.2026.07.010_bib0074","article-title":"Abstract PO3-05-08: updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER\u2013positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2026.07.010_bib0041","year":"2025","journal-title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+\/\u200bHER2- Advanced Breast Cancer (OPERA-01)"},{"issue":"9","key":"10.1016\/j.clbc.2026.07.010_bib0044","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-17-1229","article-title":"Discovery of selective estrogen receptor covalent antagonists for the treatment of er\u03b1wt and ER\u03b1MUT breast cancer","volume":"8","author":"Puyang","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.010_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105291","article-title":"Can selective estrogen receptor-\u03b1 covalent antagonist (SERCA) be a new treatment for breast cancer?","volume":"10","author":"Zagami","year":"2025","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.clbc.2026.07.010_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105290","article-title":"Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer","volume":"10","author":"Yonemori","year":"2025","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"10.1016\/j.clbc.2026.07.010_bib0046","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2025.43.16_suppl.512","article-title":"The Promise study: a presurgical randomized clinical trial of CE\/BZA vs placebo in postmenopausal women with ductal carcinoma in situ","volume":"43","author":"Kulkarni","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2026.07.010_sbref0048","series-title":"Phase IIB Trial of Bazedoxifene plus Conjugated Estrogens","year":"2024"},{"issue":"12","key":"10.1016\/j.clbc.2026.07.010_bib0063","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.annonc.2023.09.3103","article-title":"Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2\u2212 breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2","volume":"34","author":"Damodaran","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.010_bib0071","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14737140.9.1.51","article-title":"The NSABP study of Tamoxifen and Raloxifene (STAR) trial","volume":"9","author":"Vogel","year":"2009","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:09:05Z","timestamp":1788948545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1526820926001126"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.010","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Endocrine Therapies: Current Status and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}